Zealand Pharma said it is moving forward with AI-enabled protein-based obesity and metabolic disease programs through a partnership with Generate Biomedicines. Zealand plans to develop new protein therapeutics leveraging Generate Biomedicines’ AI technology, with an upfront payment of $30 million for two initial programs. The structure reflects how obesity drug development is broadening beyond small-molecule incretin approaches. Protein modalities and AI-driven discovery are increasingly used to compress early discovery timelines and widen mechanism coverage. For the biotech ecosystem, the deal also signals where capital is concentrating: differentiated modality bets tied to metabolic endpoints and a path to clinical validation. It adds to a growing list of alliances that aim to secure obesity IP before competitive windows narrow.